Study of patient characteristics, treatment patterns, < em > EGFR < /em > testing patterns and outcomes in real-world patients with < em > EGFR < /em > m < sup > + < /sup > non-small cell lung cancer

CONCLUSIONS: The majority of patients treated with first-/second-generation EGFR TKIs went on to receive osimertinib in the 2L setting, but overall, only a third of patients had received molecular testing at progression. Improved testing frequency is vital to inform treatment decisions.PMID:34544302 | DOI:10.1080/03007995.2021.1983530

Source: Current Medical Research and Opinion - September 21, 2021 Category: Research Authors: Katherine B Winfree Kristin M Sheffield Zhanglin Lin Cui Tomoko Sugihara Josephine Feliciano Source Type: research